Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q3 2016 · 10-Q
Revenue$0.00$0.00no prior Q3 2015 on file Net Income-$2.15M-$2.15MN/M vs Q3 2015 EPS Diluted-$1.95-$1.95N/M vs Q3 2015 Operating Income-$2,141,800N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
derived
ended Dec 31, 2015 · filed Feb 16, 2016 · 47 d after period end